US 10548302
Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophy
granted A61KA61K49/0008
Quick answer
US patent 10548302 (Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophy) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Feb 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 30
- CPC classes
- A61K, A61K49/0008